- Investing Ideas
- /
- Danish Pharmaceuticals & Biotech High Growth Potential Companies
Danish Pharmaceuticals & Biotech High Growth Potential Companies
Results
5
Companies with a Future performance score of at least 3, ordered by Future performance score.
5 companies
Gubra
Market Cap: DKK 6.7b
A biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.
GUBRA
DKK 413.60
7D
-2.9%
1Y
-36.4%
Novo Nordisk
Market Cap: DKK 1.9t
Engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
NOVO B
DKK 433.10
7D
-3.7%
1Y
-55.4%
ChemoMetec
Market Cap: DKK 9.2b
Engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally.
CHEMM
DKK 528.00
7D
-4.0%
1Y
34.9%
Genmab
Market Cap: DKK 83.7b
A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
GMAB
DKK 1,361.00
7D
-0.2%
1Y
-25.5%
ALK-Abelló
Market Cap: DKK 42.9b
Operates as an allergy solutions company in Europe, North America, and internationally.
ALK B
DKK 194.10
7D
1.4%
1Y
26.9%